Vaccine Production Facility
- Client
- Shionogi & Co., Ltd.
- Location
- Ikeda-cho, Ibi District, Gifu Prefecture, Japan Within UNIGEN Gifu Plant
- Scope of Work
- Engineering, Procurement, Construction and Validation (E.P.C.V)
- Year of completion
- 2023
Establishing Domestic Vaccine Commercial Production
Significant National Project for Domestic Vaccine Supply
This project is to establish commercial production of a recombinant protein vaccine using the unique Baculovirus Expression Vector System (BEVS) technology, possessed by the group company of Shionogi & Co., Ltd, and holds great social significance in contributing towards establishing a domestic vaccine manufacturing facility, addressing Japan's reliance on vaccine imports and ensuring a stable supply of domestically produced vaccines.
Leveraging our Extensive Experience in the Pharmaceutical Field
Chiyoda has constructed more than 630 pharmaceutical plants in over 60 years. Leveraging on this expertise, we successfully completed a manufacturing facility of drug substance for vaccine for Shionogi & Co., Ltd. in January 2023. The first manufacturing line was completed within a tight 8 month time schedule from the start of construction in August 2020. The second manufacturing line and associated facilities were also completed on schedule, showcasing our group’s technical expertise and project management capabilities.
Strengthening our Track Record
We will continue expanding upon the success of this project with further ventures into the growing fields of biopharmaceuticals, including cell therapy and regenerative medicine, as well as the broader biotechnology industry.